Verici Dx plc

("Verici Dx" or the "Company") 

CEO to participate in a panel at Capital Markets Day for Kidney Health  

Sara Barrington to join the discussion on lead IPOs in kidney disease in 2020
at a virtual event featuring leading Clinicians, Biotech Innovators and Federal Health Agencies
to highlight Innovation and Opportunity in Kidney Health

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its CEO, Sara Barrington, is to join a panel at an American Society of Nephrology (ASN) event on Thursday, February 11 from 8:00 a.m. - 12:30 p.m. EST.

This webinar, hosted by the American Society of Nephrology in association with Renalytix AI plc ("RenalytixAI"), the dual AIM/Nasdaq-listed artificial intelligence-enabled in vitro diagnostics company, will bring together a broad group of delegates representing the kidney health community, including leading clinicians, representatives of U.S. Government health agencies, kidney care innovators and investors focused on life sciences and medical technology, for a series of presentations and panel discussions on the challenges and innovations arising from kidney health and the market opportunity in this area.

The Capital Markets Day for Kidney Health event will feature a number of keynote addresses from leading industry figures, including:

·    Susan E. Quaggin, MD, FRCP(C), FASN; President, American Society of Nephrology; Chief, Division of Nephrology and Hypertension; Director, Feingberg Cardiovascular and Renal Research Institute, Charles Horace Mayo Professor of Medicine at Northwestern University; and

·    Steven Coca, DO, MS; Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, and co-founder of RenalytixAI.

RenalytixAI CEO, James McCullough, will also participate in a panel discussion on lead IPOs in kidney disease in 2020 in which Sara will also feature.

The full agenda and registration information can be viewed here: https://www.asn-online.org/KCMD

Sara Barrington, CEO of Verici Dx, commented:

"I am delighted to be able to participate at the American Society of Nephrology's Virtual Capital Markets Day for Kidney Health in association with RenalytixAI. Over 850,000,000 people worldwide have kidney disease and treating kidney failure is one of the most costly medical conditions globally. Verici Dx, along with other presenting companies, are fully committed to delivering better health outcomes for patients and institutions."

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.